Evidence map›Paper›PMID 39530689›Full record

ReviewmBio2024

Dimming the corona: studying SARS-coronavirus-2 at reduced biocontainment level using replicons and virus-like particles.

Grace Neilsen, Asha Maria Mathew, Jose M Castro, William M McFadden, Xin Wen, Yee T Ong, Philip R Tedbury, Shuiyun Lan, Stefan G Sarafianos

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in mBio, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Characterization of antiviral compounds using Bio-Layer Interferometry.bioRxiv : the preprint server for biology · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Grace Neilsen *Laboratory of Biochemical Pharmacology, Department of Pediatrics, Center for ViroScience and Cure, Emory University School of Medicine, Atlanta, Georgia, USA.
Asha Maria Mathew *Laboratory of Biochemical Pharmacology, Department of Pediatrics, Center for ViroScience and Cure, Emory University School of Medicine, Atlanta, Georgia, USA.
Jose M Castro *Laboratory of Biochemical Pharmacology, Department of Pediatrics, Center for ViroScience and Cure, Emory University School of Medicine, Atlanta, Georgia, USA.
William M McFaddenLaboratory of Biochemical Pharmacology, Department of Pediatrics, Center for ViroScience and Cure, Emory University School of Medicine, Atlanta, Georgia, USA.
Xin WenLaboratory of Biochemical Pharmacology, Department of Pediatrics, Center for ViroScience and Cure, Emory University School of Medicine, Atlanta, Georgia, USA.
Yee T OngLaboratory of Biochemical Pharmacology, Department of Pediatrics, Center for ViroScience and Cure, Emory University School of Medicine, Atlanta, Georgia, USA.
Philip R TedburyLaboratory of Biochemical Pharmacology, Department of Pediatrics, Center for ViroScience and Cure, Emory University School of Medicine, Atlanta, Georgia, USA.
Shuiyun LanLaboratory of Biochemical Pharmacology, Department of Pediatrics, Center for ViroScience and Cure, Emory University School of Medicine, Atlanta, Georgia, USA.ORCID 0009-0002-4101-9894
Stefan G SarafianosLaboratory of Biochemical Pharmacology, Department of Pediatrics, Center for ViroScience and Cure, Emory University School of Medicine, Atlanta, Georgia, USA.ORCID 0000-0002-5840-154X

Funding

Discovery of SARS-CoV-2 antivirals using a replicon assayR01AI167356 · NIAID · EMORY UNIVERSITY · PI Stefan G Sarafianos, Zhengqiang Wang · 2022 to 2026
$3.5M
Training Program in Biochemistry, Cell and Molecular BiologyT32GM135060 · NIGMS · EMORY UNIVERSITY · PI Lawrence H. Boise, ANITA H. CORBETT · 2020 to 2026
$2.8M
Antimicrobial Resistance and Therapeutic Discovery Training ProgramT32AI106699 · NIAID · EMORY UNIVERSITY · PI Graeme L Conn, Joanna B Goldberg · 2014 to 2026
$2.7M
Structural and Biochemical Effects of Capsid-targeting Molecules on HIV-1 Capsid AssemblyF31AI174951 · NIAID · EMORY UNIVERSITY · PI WILLIAM MICHAEL MCFADDEN · 2023 to 2026
$196k
Characterization of JT-4-173, a Potent Antiviral that Inhibits HIV-1 by a Novel Mechanism of ActionF31AI179424 · NIAID · EMORY UNIVERSITY · PI Xin Wen · 2023 to 2026
$196k
HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID) F31AI174951HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID) F31AI179424HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID) R01AI167356HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID) R01AI167356-02S1HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID) T32AI106699HHS | NIH | National Institute of General Medical Sciences (NIGMS) T32GM135060NIAID NIH HHS F31 AI174951NIAID NIH HHS F31 AI179424NIAID NIH HHS R01 AI167356NIAID NIH HHS T32 AI106699NIGMS NIH HHS T32 GM135060
6 · The paper itself

Abstract

The coronavirus-induced disease 19 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infections, has had a devastating impact on millions of lives globally, with severe mortality rates and catastrophic social implications. Developing tools for effective vaccine strategies and platforms is essential for controlling and preventing the recurrence of such pandemics. Moreover, molecular virology tools that facilitate the study of viral pathogens, impact of viral mutations, and interactions with various host proteins are essential. Viral replicon- and virus-like particle (VLP)-based systems are excellent examples of such tools. This review outlines the importance, advantages, and disadvantages of both the replicon- and VLP-based systems that have been developed for SARS-CoV-2 and have helped the scientific community in dimming the intensity of the COVID-19 pandemic.

Indexed as

COVID-19RepliconSARS-CoV-2Containment of BiohazardsCOVID-19 VaccinesHumansVaccines, Virus-Like ParticleCOVID-19 VaccinesVaccines, Virus-Like ParticlecoronavirusCOVID-19drug discoveryrepliconSARS-CoV-2vaccinesvirus-like particles

Identifiers

PMID39530689
PMCPMC11633226

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.